Search

Your search keyword '"Elstrom, Rebecca"' showing total 343 results
Start Over Author "Elstrom, Rebecca"
343 results on '"Elstrom, Rebecca"'

3. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Author

Tam, Constantine S., Trotman, Judith, Opat, Stephen, Burger, Jan A., Cull, Gavin, Gottlieb, David, Harrup, Rosemary, Johnston, Patrick B., Marlton, Paula, Munoz, Javier, Seymour, John F., Simpson, David, Tedeschi, Alessandra, Elstrom, Rebecca, Yu, Yiling, Tang, Zhiyu, Han, Lynn, Huang, Jane, Novotny, William, Wang, Lai, and Roberts, Andrew W.

Published
2019
Full Text
View/download PDF

4. Figures S7 - S9 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

5. Figure S5 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

6. Table S2 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

7. Data from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Methods from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure S3 from Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Author

Song, Yuqin, primary, Zhou, Keshu, primary, Zou, Dehui, primary, Zhou, Jianfeng, primary, Hu, Jianda, primary, Yang, Haiyan, primary, Zhang, Huilai, primary, Ji, Jie, primary, Xu, Wei, primary, Jin, Jie, primary, Lv, Fangfang, primary, Feng, Ru, primary, Gao, Sujun, primary, Guo, Haiyi, primary, Zhou, Lei, primary, Elstrom, Rebecca, primary, Huang, Jane, primary, Novotny, William, primary, Wei, Rachel, primary, and Zhu, Jun, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure from Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Author

Herrera, Alex F., primary, Patel, Manish R., primary, Burke, John M., primary, Advani, Ranjana, primary, Cheson, Bruce D., primary, Sharman, Jeff P., primary, Penuel, Elicia, primary, Polson, Andrew G., primary, Liao, Chen Di, primary, Li, Chunze, primary, Schuth, Eva, primary, Vaze, Anjali, primary, Samineni, Divya, primary, Elstrom, Rebecca, primary, Cooper, James, primary, and Diefenbach, Catherine, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Data from Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Author

Herrera, Alex F., primary, Patel, Manish R., primary, Burke, John M., primary, Advani, Ranjana, primary, Cheson, Bruce D., primary, Sharman, Jeff P., primary, Penuel, Elicia, primary, Polson, Andrew G., primary, Liao, Chen Di, primary, Li, Chunze, primary, Schuth, Eva, primary, Vaze, Anjali, primary, Samineni, Divya, primary, Elstrom, Rebecca, primary, Cooper, James, primary, and Diefenbach, Catherine, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Data from Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Author

Song, Yuqin, primary, Zhou, Keshu, primary, Zou, Dehui, primary, Zhou, Jianfeng, primary, Hu, Jianda, primary, Yang, Haiyan, primary, Zhang, Huilai, primary, Ji, Jie, primary, Xu, Wei, primary, Jin, Jie, primary, Lv, Fangfang, primary, Feng, Ru, primary, Gao, Sujun, primary, Guo, Haiyi, primary, Zhou, Lei, primary, Elstrom, Rebecca, primary, Huang, Jane, primary, Novotny, William, primary, Wei, Rachel, primary, and Zhu, Jun, primary

Published
2023
Full Text
View/download PDF

13. Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Author

Mehta, Amitkumar, primary, Farooq, Umar, additional, Chen, Andy, additional, McGuirk, Joseph P., additional, Ly, Thomas, additional, Wong, Lilly, additional, Cooley, Sarah, additional, Valamehr, Bahram, additional, Elstrom, Rebecca, additional, Chu, Yu-Waye, additional, and Park, Jae H., additional

Published
2022
Full Text
View/download PDF

14. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Author

Wilson, Wyndham H., Young, Ryan M., Schmitz, Roland, Yang, Yandan, Pittaluga, Stefania, Wright, George, Lih, Chih- Jian, Williams, P. Mickey, Shaffer, Arthur L., Gerecitano, John, de Vos, Sven, Goy, Andre, Kenkre, Vaishalee P., Barr, Paul M., Blum, Kristie A., Shustov, Andrei, Advani, Ranjana, Fowler, Nathan H., Vose, Julie M., Elstrom, Rebecca L., Habermann, Thomas M., Barrientos, Jacqueline C., McGreivy, Jesse, Fardis, Maria, Chang, Betty Y., Clow, Fong, Munneke, Brian, Moussa, Davina, Beaupre, Darrin M., and Staudt, Louis M.

Subjects
Biological sciences, Health
Abstract

The two major subtypes of diffuse large B cell lymphoma (DLBCL)--activated B cell-like (ABC) and germinal center B cell-like (GCB)--arise by distinct mechanisms, with ABC selectively acquiring mutations that target the B cell receptor (BCR), fostering chronic active BCR signaling (1). The ABC subtype has a ~40% cure rate with currently available therapies, which is worse than the rate for GCB DLBCL, and highlights the need for ABC subtype-specific treatment strategies (2). We hypothesized that ABC, but not GCB, DLBCL tumors would respond to ibrutinib, an inhibitor of BCR signaling. In a phase 1/2 clinical trial that involved 80 subjects with relapsed or refractory DLBCL, ibrutinib produced complete or partial responses in 37% (14/38) of those with ABC DLBCL, but in only 5% (1/20) of subjects with GCB DLBCL (P = 0.0106). ABC tumors with BCR mutations responded to ibrutinib frequently (5/9; 55.5%), especially those with concomitant myeloid differentiation primary response 88 (MYD88) mutations (4/5; 80%), a result that is consistent with in vitro cooperation between the BCR and MYD88 pathways. However, the highest number of responses occurred in ABC tumors that lacked BCR mutations (9/29; 31%), suggesting that oncogenic BCR signaling in ABC does not require BCR mutations and might be initiated by non-genetic mechanisms. These results support the selective development of ibrutinib for the treatment of ABC DLBCL., Nuclear factor kappa B (NF-κB) activity sustains viability of ABC, but not GCB, DLBCL cell lines (3) and is constitutively activated by signals from the BCR and MYD88 pathways (4,5). [...]

Published
2015

15. Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Author

Herrera, Alex F., primary, Patel, Manish R., additional, Burke, John M., additional, Advani, Ranjana, additional, Cheson, Bruce D., additional, Sharman, Jeff P., additional, Penuel, Elicia, additional, Polson, Andrew G., additional, Liao, Chen Di, additional, Li, Chunze, additional, Schuth, Eva, additional, Vaze, Anjali, additional, Samineni, Divya, additional, Elstrom, Rebecca, additional, Cooper, James, additional, and Diefenbach, Catherine, additional

Published
2022
Full Text
View/download PDF

16. Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Author

Bachanova, Veronika, primary, Ghobadi, Armin, additional, Patel, Krish, additional, Park, Jae H, additional, Flinn, Ian W., additional, Shah, Prutha, additional, Wong, Carol, additional, Bickers, Cara, additional, Szabo, Peter, additional, Wong, Lilly, additional, Valamehr, Bahram, additional, Atwal, Siminder, additional, Chu, Yu-Waye, additional, Elstrom, Rebecca, additional, and Strati, Paolo, additional

Published
2021
Full Text
View/download PDF

17. Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma

Author

Patel, Krish, primary, Bachanova, Veronika, additional, Goodman, Aaron M, additional, Pagel, John M., additional, Griffis, Kelly, additional, Anderson, Marlisa, additional, Atwal, Siminder, additional, Bickers, Cara, additional, Szabo, Peter, additional, Wong, Lilly, additional, Chu, Yu-Waye, additional, Elstrom, Rebecca, additional, and Strati, Paolo, additional

Published
2021
Full Text
View/download PDF

19. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

Author

Straus, David J., Hamlin, Paul A., Matasar, Matthew J., Lia Palomba, Maria, Drullinsky, Pamela R., Zelenetz, Andrew D., Gerecitano, John F., Noy, Ariela, Hamilton, Audrey M., Elstrom, Rebecca, Wegner, Brett, Wortman, Katy, and Cella, David

Published
2015
Full Text
View/download PDF

20. Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).

Author

Strati, Paolo, primary, Bachanova, Veronika, additional, Goodman, Aaron, additional, Pagel, John M., additional, Castro, Januario E., additional, Griffis, Kelly, additional, Anderson, Marlisa, additional, Atwal, Siminder K., additional, Bickers, Cara, additional, Fremgen, Daniel, additional, Ly, Christina, additional, Cooley, Sarah A., additional, Elstrom, Rebecca L., additional, and Patel, Krish, additional

Published
2021
Full Text
View/download PDF

25. Contributors

Author

Abbruzzese, James L., primary, Abeloff, Martin D., additional, Abou-Alfa, Ghassan K., additional, Abrahm, Janet L., additional, Abrams, Jeffery S., additional, Acs, Geza, additional, Aisner, Joseph, additional, Aisner, Seena C., additional, Alani, Rhoda M., additional, Alberts, Steven R., additional, Ambinder, Richard F., additional, Andritsos, Leslie A., additional, Appelbaum, Frederick R., additional, Apte, Sachin, additional, Armitage, James O., additional, Armstrong, Deborah, additional, Bagheri, Mamad M., additional, Balch, Charles M., additional, Balducci, Lodovico, additional, Beghé, Claudia, additional, Benjamin, Robert, additional, Bennett, Charles L., additional, Berkowitz, Ross Stuart, additional, Bernstein, Donna, additional, Bishop, Michael R., additional, Blot, William J., additional, Blumgart, Leslie, additional, Bommer, Guido T., additional, Borowitz, Michael J., additional, Brahmer, Julie R., additional, Bramwell, Viven H.C., additional, Brock, Malcom V., additional, Bydon, Ali, additional, Cairo, Mitchell S., additional, Campana, Dario, additional, Carbone, David P., additional, Carter, H. Ballentine, additional, Chadha, Manpreet K., additional, Chan, Daniel W., additional, Chang, Alfred E., additional, Cheung, Nai-Kong V., additional, Christian, Michaele, additional, Clarke, Michael F., additional, Cmelak, Anthony, additional, Coccia, Peter F., additional, Cohen, Alfred M., additional, Coleman, Robert E., additional, Compton, Carolyn, additional, Cooley, Linda D., additional, Cortes, Jorge, additional, Courtneidge, Sara A., additional, Cowan, Kenneth H., additional, Culkin, Daniel J., additional, Dalmau, Josep, additional, D'Angio, Giulio J., additional, Dawson, Laura, additional, Deitcher, Steven R., additional, DeMatteo, Ronald P., additional, DeSimone, Philip A., additional, DeWeese, Theodore L., additional, Digumarthy, Subba R., additional, Dispenzieri, Angela, additional, Dome, Jeffrey S., additional, Donohue, John H., additional, Doroshow, James H., additional, Drebin, Jeffery A., additional, Duda, Dan G., additional, Duffy, Austin, additional, Duska, Linda R., additional, Eisenberger, Mario A., additional, Elstrom, Rebecca L., additional, Erler, Janine T., additional, Ewer, Michael S., additional, Fearon, Eric R., additional, Fecher, Leslie A., additional, Fichera, Alessandro, additional, Filipovich, Alexandra H., additional, Fitzner, Karen A., additional, Foote, Robert L., additional, Foran, James M., additional, Forastiere, Arlene A., additional, Ford, James M., additional, Freifeld, Alison G., additional, Freter, Carl E., additional, Fuller, Arlan F., additional, Furth, Emma E., additional, Garofalo, Michael C., additional, Gebhardt, Mark C., additional, Gerber, N. Lynn, additional, Gharia, Manish, additional, Giaccia, Amato J., additional, Gilbert, Mark R., additional, Glaspy, John, additional, Glover, Katrina Y., additional, Gokaslan, Ziya L., additional, Gökbuget, Nicola, additional, Goldstein, Donald Peter, additional, Gonzalez, Adriana, additional, Goodman, Anne Kathryn, additional, Gordon, Ellen, additional, Green, Daniel M., additional, Grever, Michael R., additional, Grigg, Andrew, additional, Grochow, Louise, additional, Gross, Thomas G., additional, Grossman, Stuart A., additional, Gunderson, Leonard L., additional, Gunkel, Juliet, additional, Gutierrez, Martin, additional, Habermann, Thomas M., additional, Haik, Barrett G., additional, Hainsworth, John D., additional, Hallahan, Dennis, additional, Hanna, Nader N., additional, Harris, Eleanor E.R., additional, Hawk, Ernie, additional, Heideman, Nancy H., additional, Heideman, Richard L., additional, Helman, Lee J., additional, Hochberg, Jessica, additional, Hoelzer, Dieter, additional, Holen, Ingunn, additional, Horning, Sandra J., additional, Huang, Kim, additional, Illei, Peter B., additional, Jaffe, Elaine S., additional, Jagannath, Sanjay B., additional, Jain, Rakesh K., additional, Jarnagin, William, additional, Jhingran, Anuja, additional, Johnson, David H., additional, Jones, Heather, additional, Judy, Kevin D., additional, Juergens, Rosalyn A., additional, Kant, Jeffrey A., additional, Kantarjian, Hagop, additional, Karcioglu, Zeynel A., additional, Karyadi, Danielle M., additional, Kased, Norbert, additional, Kastan, Michael B., additional, Kaul, Daniel R., additional, Kawaoka, John, additional, Kemeny, Margaret, additional, Kemeny, Nancy, additional, Kensler, Thomas W., additional, Kleinberg, Lawrence R., additional, Kobrinsky, Boris, additional, Kowalski, Jeanne, additional, Kummar, Shivaani, additional, Lal, Geeta, additional, Lambert, Paul F., additional, Lange, Julie R., additional, Laskin, Janessa, additional, Lee, Fred, additional, Lee, Susanna I., additional, Lees, Jacqueline, additional, Lenzi, Renato, additional, Lerman, Caryn, additional, Lipton, Allan, additional, Loprinzi, Charles L., additional, Lozanski, Gerard, additional, Lustig, Robert, additional, Machtay, Mitchell, additional, Maity, Amit, additional, Malik, Uzma, additional, Manatt, C. Scott, additional, Mansour, John C., additional, Massion, Pierre P., additional, Mayer, R. Samuel, additional, McCormick, Beryl, additional, McDonald, Charles J., additional, McDougall, Ross, additional, McKenna, W. Gillies, additional, Meranze, Steven, additional, Metz, James M., additional, Meyskens, Frank L., additional, Michelassi, Fabrizio, additional, Mikkilineni, Radha, additional, Mock, Victoria, additional, Mohiuddin, Mohammed, additional, Montie, James, additional, Morton, A. Ross, additional, Murgo, Anthony J., additional, Neff, James R., additional, Nelson, William G., additional, Nesbit, Suzanne, additional, Niederhuber, John E., additional, O'Connor, Tracey, additional, O'Dorisio, Thomas, additional, Offit, Kenneth, additional, Onciu, Mihaela, additional, O'Reilly, Eileen M., additional, Ostrander, Elaine A., additional, O'Sullivan, Brian, additional, Pardoll, Drew M., additional, Park, Catherine K., additional, Patterson, Freda, additional, Pavletic, Steven Z., additional, Perry, Michael C., additional, Peterson, LoAnn C., additional, Phillips, Peter C., additional, Piantadosi, Steven, additional, Pili, Robert, additional, Pisters, Peter W.T., additional, Pittelkow, Mark R., additional, Plastaras, John P., additional, Platz, Elizabeth A., additional, Pribaz, Julian, additional, Pruitt, Amy A., additional, Pui, Ching-Hon, additional, Putnam, Joe Bill, additional, Quon, Harry, additional, Raber, Martin N., additional, Rajkumar, S. Vincent, additional, Regine, William F., additional, Ritter, Mark, additional, Roberts, John Robert, additional, Robinson-Bostom, Leslie, additional, Rodriguez, Ronald, additional, Rodriguez-Galindo, Carlos, additional, Rosenfeld, Myrna, additional, Rosenthal, Nadia, additional, Rubenstein, James L., additional, Rubin, Brian P., additional, Rupani, Reena, additional, Rusch, Valerie W., additional, Russell, Anthony H., additional, Ryan, Charles J., additional, Sacchini, Vergilio, additional, Sandler, Alan B., additional, Sandler, Howard, additional, Sandlund, John T., additional, Santana, Victor M., additional, Schnoll, Robert A., additional, Sciubba, Daniel M., additional, Seiden, Michael V., additional, Sekeres, Mikkael A., additional, Sharfman, William H., additional, Sharma, Ricky A., additional, Sideras, Kostandinos, additional, Silver, Kenneth, additional, Small, Eric J., additional, Smith, David C., additional, Sneed, Penny K., additional, Snow, Stephen N., additional, Sokoll, Lori J., additional, Sovak, Mika A., additional, Speyer, James L., additional, Spira, Alex I., additional, Springfield, Dempsey, additional, Spunt, Sheri L., additional, Stewart, Daniel, additional, Strickland, Paul T., additional, Sugden, Bill, additional, Sutcliffe, Siobhan, additional, Sun, Weijing, additional, Tallman, Martin S., additional, Talmadge, James E., additional, Tefferi, Ayalew, additional, Thom, Peter, additional, Thompson, Craig B., additional, Tisdale, Michael J., additional, Tobinai, Kensei, additional, Tomaszewski, Joseph E., additional, Topalian, Suzanne L., additional, Torti, Frank M., additional, Trump, Donald L., additional, Vallis, Katherine A., additional, Varadhachary, Gauri R., additional, Vemulapalli, Sreenivas, additional, Visvanathan, Kala, additional, Wagner-Johnston, Nina D., additional, Wahl, Richard L., additional, Watanabe, Toshiki, additional, Weber, Barbara L., additional, Weber, Sharon, additional, Weigel, Ronald J., additional, Weissman, Irving L., additional, Westra, William, additional, Wilson, Kathleen S., additional, Wilson, Wyndham H., additional, Wolff, Antonio C., additional, Wong, Sandra L., additional, Wood, Gary S., additional, Wyatt, Lance S., additional, Zakarija, Anaadriana, additional, Zaks, Tal Z., additional, and Zell, Jason A., additional

Published
2008
Full Text
View/download PDF

27. Treatment of Patients with Relapsed or Refractory Mantle–Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase

Author

Song, Yuqin, primary, Zhou, Keshu, additional, Zou, Dehui, additional, Zhou, Jianfeng, additional, Hu, Jianda, additional, Yang, Haiyan, additional, Zhang, Huilai, additional, Ji, Jie, additional, Xu, Wei, additional, Jin, Jie, additional, Lv, Fangfang, additional, Feng, Ru, additional, Gao, Sujun, additional, Guo, Haiyi, additional, Zhou, Lei, additional, Elstrom, Rebecca, additional, Huang, Jane, additional, Novotny, William, additional, Wei, Rachel, additional, and Zhu, Jun, additional

Published
2020
Full Text
View/download PDF

28. Trial in progress: A phase III, randomized, open-label study comparing zanubrutinib plus rituximab versus bendamustine plus rituximab in patients with previously untreated mantle cell lymphoma (MCL).

Author

Dreyling, Martin H., primary, Tam, Constantine Si Lun, additional, Wang, Michael, additional, Smith, Stephen Douglas, additional, Ladetto, Marco, additional, Huang, Huiqiang, additional, Elstrom, Rebecca L., additional, Co, Melannie, additional, Holmgren, Eric, additional, Huang, Jane, additional, and Le Gouill, Steven, additional

Published
2020
Full Text
View/download PDF

35. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

Author

Song, Yuqin, primary, Gao, Quanli, additional, Zhang, Huilai, additional, Fan, Lei, additional, Zhou, Jianfeng, additional, Zou, Dehui, additional, Li, Wei, additional, Yang, Haiyan, additional, Liu, Ting, additional, Wang, Quanshun, additional, Lv, Fangfang, additional, Guo, Haiyi, additional, Yang, Liudi, additional, Elstrom, Rebecca, additional, Huang, Jane, additional, Novotny, William, additional, Wei, Vivian, additional, and Zhu, Jun, additional

Published
2019
Full Text
View/download PDF

36. Tislelizumab (BGB-A317) for Relapsed/Refractory Classical Hodgkin Lymphoma: Preliminary Efficacy and Safety Results from a Phase 2 Study

Author

Song, Yuqin, primary, Gao, Quanli, additional, Zhang, Huilai, additional, Fan, Lei, additional, Zhou, Jianfeng, additional, Zou, Dehui, additional, Li, Wei, additional, Yang, Haiyan, additional, Liu, Ting, additional, Wang, Quanshun, additional, Lv, Fangfang, additional, Yang, Yu, additional, Guo, Haiyi, additional, Yang, Liudi, additional, Elstrom, Rebecca, additional, Huang, Jane, additional, Novotny, William, additional, Wei, Vivian, additional, and Zhu, Jun, additional

Published
2018
Full Text
View/download PDF

38. Additional file 1: Table S1. of Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

Author

Pera, Benet, Tang, Tiffany, Marullo, Rossella, Yang, Shao-Ning, Haelee Ahn, Jayeshkumar Patel, Elstrom, Rebecca, Ruan, Jia, Furman, Richard, Leonard, John, Cerchietti, Leandro, and Martin, Peter

Abstract

Toxicity. Highest grade of treatment-emergent adverse events encountered at the four different dose levels. (DLs). DL1: azacitidine (AZA) 55 mg/m2 days 1–5 and vorinostat (VST) 300 mg BID days 1–7. DL2: AZA 75 mg/m2 days 1–5 and VST 200 mg BID days 1–7. DL3: AZA 55 mg/m2 days 1–5 and VST 300 mg BID days 1–14. DL4: AZA 75 mg/m2 days 1–5 and VST 200 mg BID days 1–14. (DOC 57.0 kb)

Published
2016
Full Text
View/download PDF

39. Additional file 2: Table S2. of Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients

Author

Pera, Benet, Tang, Tiffany, Marullo, Rossella, Yang, Shao-Ning, Haelee Ahn, Jayeshkumar Patel, Elstrom, Rebecca, Ruan, Jia, Furman, Richard, Leonard, John, Cerchietti, Leandro, and Martin, Peter

Abstract

Treatment response at the four different dose levels (DLs). DL1: Azacitidine (AZA) 55 mg/m2 days 1–5 and vorinostat (VST) 300 mg BID days 1–7. DL2: AZA 75 mg/m2 days 1–5 and VST 200 mg BID days 1–7. DL3: AZA 55 mg/m2 days 1–5 and VST 300 mg BID days 1–14. DL4: AZA 75 mg/m2 days 1–5 and VST 200 mg BID days 1–14. (DOC 39 kb)

Published
2016
Full Text
View/download PDF

40. Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma

Author

Zelenetz, Andrew D., primary, Salles, Gilles A., additional, Mason, Kylie D, additional, Casulo, Carla, additional, Le Gouill, Steven, additional, Sehn, Laurie H, additional, Tilly, Hervé, additional, Cartron, Guillaume, additional, Chamuleau, Martine ED, additional, Goy, Andre, additional, Tam, Constantine S., additional, Lugtenburg, Pieternella J, additional, Elstrom, Rebecca, additional, Farazi, Thalia, additional, Liu, Juan, additional, Szafer-Glusman, Edith, additional, Mobasher, Mehrdad, additional, and Morschhauser, Franck, additional

Published
2016
Full Text
View/download PDF

41. PET Imaging of Lymphoma, An Issue of PET Clinics

Author

Schuster, Stephen J., Elstrom, Rebecca L., Schuster, Stephen J., and Elstrom, Rebecca L.

Subjects
Lymphomas--Imaging, Tomography, Emission
Abstract

This issue provides a complete update on PET imaging of lymphoma, starting with a clinical assessment of lymphoma and the role of medical imaging. The role of structural imaging in lymphoma is then discussed. From a Nuclear Medicine perspective, FDG-PET in lymphoma is reviewed, as is the role of FDG-PET in pediatric lymphoma. Next, the role of non-FDG tracers in lymphoma is reviewed. Other articles cover the role of fMRI and optical imaging in lymphoma, the role of diffusion-weighted MRI in lymphoma, FDG-PET in personalization of therapy in patients with lymphoma, and PET and radiation oncology in lymphoma.

Published
2012

43. Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma.

Author

Zelenetz, Andrew David, primary, Salles, Gilles A., additional, Mason, Kylie D., additional, Casulo, Carla, additional, Le Gouill, Steven, additional, Sehn, Laurie Helen, additional, Tilly, Herve, additional, Cartron, Guillaume, additional, Chamuleau, Martine E.D., additional, Goy, Andre, additional, Tam, Constantine, additional, Lugtenburg, Pieternella J., additional, Elstrom, Rebecca L., additional, Hsu, Wanling, additional, Mobasher, Mehrdad, additional, and Morschhauser, Franck, additional

Published
2016
Full Text
View/download PDF

44. Durable Responses with the Metronomic Regimen RT-PEPC in Elderly Patients with Recurrent Mantle Cell Lymphoma

Author

Ruan, Jia, Martin, Peter, Coleman, Morton, Furman, Richard R., Cheung, Ken, Faye, Adam, Elstrom, Rebecca, Lachs, Mark, Hajjar, Katherine A., and Leonard, John P.

Subjects
Aged, 80 and over, Male, Neovascularization, Pathologic, Antibodies, Monoclonal, Lymphoma, Mantle-Cell, Middle Aged, Article, Thalidomide, Antibodies, Monoclonal, Murine-Derived, Treatment Outcome, Recurrence, Procarbazine, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Prednisone, Female, Rituximab, Cyclophosphamide, Aged, Etoposide
Abstract

Targeting the tumor microenvironment and angiogenesis is a novel lymphoma therapeutic strategy. The authors report safety, activity, and angiogenic profiling results with the rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide (RT-PEPC) regimen in patients with recurrent mantle cell lymphoma (MCL).RT-PEPC included induction (Months 1-3) of rituximab 4 times weekly, daily thalidomide (50 mg), and PEPC followed by maintenance thalidomide (100 mg), oral PEPC titrated to the neutrophil count, and rituximab every 4 months. Endpoints included safety, efficacy, quality of life (QoL), and translational studies, including tumor angiogenic phenotyping, plasma vascular endothelial growth factor (VEGF), and circulating endothelial cells.Twenty-five patients were enrolled, and 22 were evaluable. The median age was 68 years (range, 52-81 years), 24 patients (96%) had stage III or IV disease, 18 patients (72%) had an International Prognostic Index (IPI) score of 3 to 5, and 20 patients (80%) had high-risk Mantle Cell International Prognostic Index (MIPI) scores. Patients had received a median of 2 previous therapies (range, 1-7 previous therapies), and 15 patients (60%) had progressed on bortezomib. At a median follow-up of 38 months, the overall response rate was 73% (complete response [CR]/unconfirmed CR rate, 32%; partial response [PR] rate, 41%; n = 22 patients), and the median progression-free survival was 10 months. Four CRs were ongoing (or =6 months,or =31 months,or =48 months, andor =50 months). Toxicities included grade 1 and 2 fatigue, rash, neuropathy, and cytopenias, including grade 1 and 2 thrombocytopenia (64%) and grade 3 and 4 neutropenia (64%). Two thromboses and 5 episodes of grade 3 or 4 infections occurred. QoL was maintained or improved. Correlative studies demonstrated tumor autocrine angiogenic loop (expression of VEGF A and VEGF receptor 1) and heightened angiogenesis and lymphangiogenesis in stroma. Plasma VEGF levels and circulating endothelial cells trended down with treatment.RT-PEPC had significant and durable activity in MCL with manageable toxicity and maintained QoL. Novel, low-intensity approaches warrant further evaluation, potentially as initial therapy in elderly patients.

Published
2010

45. Multicenter, phase III, open-label, randomized study in relapsed/refractory CLI, to evaluate the benefit of GDC-0199 (ABT-199) plus rituximah compared with bendamustine plus rituximab.

Author

Mobasher, Mehrdad, Huang, Jane, Elstrom, Rebecca L., Elhamy, Mostafa, Bernaards, Coen, Hallek, Michael J., Hillmen, Peter, Kater, Arnon Philip, Kipps, Thomas J., Seymour, John Francis, Mobasher, Mehrdad, Huang, Jane, Elstrom, Rebecca L., Elhamy, Mostafa, Bernaards, Coen, Hallek, Michael J., Hillmen, Peter, Kater, Arnon Philip, Kipps, Thomas J., and Seymour, John Francis

Published
2014

48. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

Author

Straus, David J., primary, Hamlin, Paul A., additional, Matasar, Matthew J., additional, Lia Palomba, Maria, additional, Drullinsky, Pamela R., additional, Zelenetz, Andrew D., additional, Gerecitano, John F., additional, Noy, Ariela, additional, Hamilton, Audrey M., additional, Elstrom, Rebecca, additional, Wegner, Brett, additional, Wortman, Katy, additional, and Cella, David, additional

Published
2014
Full Text
View/download PDF

49. Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with131I-tositumomab

Author

Elstrom, Rebecca L., primary, Ruan, Jia, additional, Christos, Paul J., additional, Martin, Peter, additional, Lebovic, Daniel, additional, Osborne, Joseph, additional, Goldsmith, Stanley, additional, Greenberg, June, additional, Furman, Richard R., additional, Avram, Anca, additional, Putman, Ryan, additional, Chapman, Erica, additional, Mazumdar, Madhu, additional, Griffith, Kent, additional, Coleman, Morton, additional, Leonard, John P., additional, and Kaminski, Mark S., additional

Published
2014
Full Text
View/download PDF

50. Multicenter, phase III, open-label, randomized study in relapsed/refractory CLL to evaluate the benefit of GDC-0199 (ABT-199) plus rituximab compared with bendamustine plus rituximab.

Author

Mobasher, Mehrdad, primary, Huang, Jane, additional, Elstrom, Rebecca L., additional, Elhamy, Mostafa, additional, Bernaards, Coen, additional, Hallek, Michael J., additional, Hillmen, Peter, additional, Kater, Arnon Philip, additional, Kipps, Thomas J., additional, and Seymour, John Francis, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results